Winners of the 16th Pharma Awards
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.
CPHI Worldwide has announced the winners of the prestigious 2019 CPHI Pharma Awards – celebrating the industry’s top innovators, performers and outstanding achievements across 13 categories, spanning the entire industry supply chain. The winners have been recognised for delivering excellence in pharma and were unveiled during an invitation-only ceremony on the opening evening of CPHI Worldwide in Frankfurt.
The prestigious ‘CEO of the Year’ award has been bestowed upon Dr Ge Li, Founder, Chairman and CEO of WuXi AppTec, who was chosen for his significant contribution to the global biopharma R&D industry. Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.
For the second time in 3 years, Cambrex was awarded the ‘API Development’ category for their Crystallisation Screening and Process Development Service. The service has bridged the gap between the bench and manufacturing plat, providing controlled, robust and scalable crystallization processes. Hovione received a ‘highly commended’ acknowledgement for their Process Ranking of Inputs from Manufacturing (PRIME).
John Chiminski, Chair and CEO at Catalent Pharma Solutions, won the ‘Lifetime Achievement’ award for his accomplishments spanning more than three decades. These include the last 10 years at Catalent, during which time the company has become a true benchmark of advanced delivery technologies, development, and manufacturing solutions.
The ‘Formulation’ award was given to Nanoform for its controlled expansion of supercritical solutions (CESS). Spraying Systems Co./Fluid Air Inc. were bestowed with the ‘Manufacturing Technology and Equipment’ award for their PolarDry’ – the Cooler Technology. Cited as the future of spray drying, it utilises electrostatic technology to prevent against API loss, degradation, and denaturalisation.
Univercells received the ‘Bioprocessing and Manufacturing’ award in recognition of its NevoLine Platform, which is a bioproduction system for vaccines. The ‘Regulatory Procedures and Compliance’ prize was given to Merck Healthcare KGaA for ‘Project SARA’ (Smart Assistant for Regulatory Affairs).
The ‘Analysis, Testing, and Quality Control’ category was claimed by MedPharm for pioneering the regulatory approval of topical products using in vitro bioequivalence. MedPharm is the first contract research organisation to gain regulatory approval using in vitro models to demonstrate the bioequivalence of a generic formulation compared to the originator.
SCHOTT Pharmaceutical Systems and W.L. Gore & Associates received the ‘Packaging’ award for its syriQ BioPure – a silicone-free syringe – whilst Hoffmann Neopac was highly commended for their STYLO Spatula applicator.
The winner of the ‘Pharma Service Company of the Year Award’ is Lonza Pharma & Biotech. The company is recognised for its integrated global services offering that spans the pharmaceutical, biotech, consumer health and specialty chemicals market.
In ‘Contract Services and Outsourcing’ Nanopharm Ltd – an Aptar Pharma company – was selected as the winner for SmartTrack, with CMAC being highly commended for their CMAC National Facility.
Finally, the award for ‘Drug Delivery and Devices’ was given to Phillips-Medisize for its Connected Health Platform, and the ‘Supply Chain, Logistics and Distribution’ category was given to Kemiex AG.
Tara Dougal, Head of Content at Informa, commented: “The judges noted that this year our entries possessed an extremely high standard. All of the finalists would have made outstanding winners in previous years. On behalf of CPHI Worldwide, I would like to extend my congratulations to all the winners and commend all of the finalists. What you are doing is of tremendous benefit to the industry, but more importantly, it is also directly contributing to improved patient experiences globally.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...